Hematologic Oncology

The prospect of combining PD-1 inhibitors with existing therapies, particularly brentuximab vedotin, is emerging as the most exciting new development in advancing the treatment of patients with Hodgkin lymphoma, raising the possibility of improving the cure rates in a disease where standard strategies have already produced notable results.

Acute myeloid leukemia and myelodysplastic syndromes are the two most common hematologic malignancies of the myeloid lineage origin and both are more common in older patients.

The FDA has granted the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin a breakthrough therapy designation as a potential treatment for acute lymphoblastic leukemia.

Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

The FDA has granted an orphan drug designation to the next-generation hypomethylating agent guadecitabine as a potential treatment for patients with acute myeloid leukemia.

Limited clinical evaluation suggests a potentially major role for immune checkpoint inhibition in the treatment of lymphomas, but early success has also raised many questions.

Molecular profiling of every patient with acute myelogenous leukemia may hold the key to better treatment in the future.

Fitness, age, and disease risk status form the basis for decision-making about first-line therapy for chronic lymphocytic leukemia.

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

A Giant of Cancer Care anticipates that CAR therapy will be beneficial not only in hematologic cancers, where it has proved effective, but also in solid tumors.

The anti-CD20 agent obinutuzumab improved overall response and had acceptable toxicity compared with rituximab in patients with relapsed indolent non-Hodgkin Lymphoma, according to the final results from the GAUSS study.

Grzegorz S. Nowakowski, MD, responds to questions raised regarding the use of immunohistochemistry in his phase II study, as well as future plans for the investigation of R2-CHOP in non-GCB DLBCL.

My path to becoming an oncologist was a little different from most, but like so many others, I was inspired by a practicing physician who showed me what medicine truly can be.

The FDA has approved the antibody-drug conjugate brentuximab vedotin as a consolidation therapy following autologous stem cell transplantation in patients with Hodgkin lymphoma who are at risk of relapse or progression.

John C. Byrd, MD, discusses receiving the American Society of Hematology's 2015 William Dameshek Prize for his numerous therapeutic breakthroughs in chronic lymphocytic leukemia, his impactful career, and his goals for the future.

Ibrutinib had an overall response rate of 37% in patients with activated B-cell-like diffuse large B-cell lymphoma.

The utilization of idelalisib increased substantially between the first and second quarters of 2015, representing promising growth in a highly competitive setting.

Tahir Latif, MD, discusses results of a recent study which found that men may have a lower rate of survival among patients with diffuse large B-cell lymphoma.

Gilles A. Salles, MD, PhD, discussed treatment regimens being developed for follicular lymphoma.

Monotherapy with blinatumomab has demonstrated promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia.